TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07282873: A Phase I/II, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of the TEAD Inhibitor TYK-01054 Capsules in Patients With Locally Advanced or Metastatic Advanced

Sponsor: TYK Medicines, Inc · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 219 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07282873 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07282873 Rescue Dossier →